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ABSTRACT
Compositions for treating tissue damage from ischemia
contain PBN, or active derivatives thereof, which are active

during ischemia in preventing ATP depletion of the cells
which predisposes them to subsequent injury during reper
fusion, and which are active during reperfusion as oxygen
radical scavengers, in a suitable pharmaceutical carrier for
systemic or local administration, especially to the CNS,

spinal column and eyes. Based on animal studies, the dosage
for treating damage due to stroke is in the range of 10 to 300

mg/kg. Similar dosages are useful in treating damage result
ing from free radical generation during in?ammation, either

Yanev et al., Oxygen Free Radicals in Shock, Int.

as a product of infection or exposure to in?ammatory agents

Work-Shop, Florence 1985, pp. 193-196 (Karger, Basel

or abusive agents, including drugs and alcohol.

1986).
Ilieva et al., Neurosciences, vol. 12, pp. 223-227.
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PHENYL BUTYL NITRONE COMPOSITIONS
AND METHODS FOR TREATMENT OF
OXIDATIVE TISSUE DAMAGE

Free radicals have been postulated to be mediators of

reperfusion damage. The important production sites of such
radicals as the superoxide (02-) and hydroxyl (0H) species
are the mitochondrial respiratory chain and the sequences

catalyzed by cyclooxygenase and lipoxygenase. However,

Matter enclosed in heavy brackets [ ] appears in the
original patent but forms no part of this reissue speci?

radicals are also formed furing autoxidation of many com

pounds (e.g., catecholarnines). Several ischernic events

cation; matter printed in italics indicates the additions
made by reissue.
This application is a Reissue ofSer. No. 07/422,651, US.
Pat. No. 5,025,032.

favor a spurt of free-radical formation, e.g., those causing

oxidation of polyenoic free fatty acids, release and reuptake
of catecholarrrines, and oxidation of hypoxanthine by xan
thine oxidase. Although all these events occur during recir

BACKGROUND OF THE INVENTION

culation, when the O2 supply is restored, they represent
metabolic cascades triggered by agohist-receptor interac

This is generally in the area of compositions and methods
for use thereof for the treatment of oxidative tissue damage
such as that resulting from ischemia or in?ammation,

tions, energy failure, and/or calcium in?ux during the insult.
Although free radical formation is a likely cause of ischernic
damage, it has been di?icult to directly demonstrate that
such formation occurs and/or that it is su?iciently pro

wherein the active compounds are phenyl butylnitrone

nounced to overwhelm the antioxidative defense of the

(PBN) or derivatives thereof.
Oxygenated tissue suffers damage, in many cases perma

nent damage, if it becomes ischernic and is then reperfused.
Oxygen free radicals have been implicated in the injury.
Brain appears to be uniquely susceptible to ischernia/reper
fusion injury, and neurons are more susceptible than glial
cells. Certain areas of the brain, for example, the hippoc
ampus and spinal cord, are more susceptible than other
regions of the brain. As a result, ischernia/reperfusion injury
to brain may have a multiplicative effect simply because of
the necessity for complete integrity of all regions in order to
have proper functioning.

tissue, Curran, et al., Mol. Cell. Biol. 5, 167-172 (1985). In
20

conclusively shown that free-radical damage to unsaturated
acyl chains in phospholipids, to protein, or to nucleic acids
25

16, 947-953 (1988), document a signi?cant amount of

evidence implicating oxidative damage in head and spinal

events may underlie such gross functional aberrations as
35

(A) calcium mediated cell death, (B) excitotoxic damage
(glutamate buildup), (C) free radical events and (D) acidosis.
It is likely that all four basic mechanisms are either inter
related or contribute collectively to the injury observed.
It now seems likely that selective neuronal vulnerability

pounds have been proposed as potentially being effective.
45

been added to reperfusion media and may limit damage to
been suggested as a means for limiting in vivo oxidative

spines and dendrites could contribute. It has never been
50

The mechanisms that cause laminar necrosis, glial
distruction, and infarction are more speculative. The inabil

ity of the cells to regulate their volume may be caused by a
molecular defect where edema is a conspicuous feature.

55

Cells that possess coupled antiporters for Na+lH+ and
Cl-IHCO3 exchange may regulate pH; at the expense of
volume regulation, so that edema may be coupled to acido
60

ponents, enhanced by the drastic lowering of pHi and/or

pHe.

demonstrated that the 21-aminosteroid (474006F), which is
known to prevent peroxidation in brain homogenate, as
described by Braughler, et al., J. Biol. Chem. 262,

age induced by three hours of unilateral carotid artery
occlusion. White and Aust and co-workers, Adv. Free Radi
cal Biol. Med. 1, 1—l7 (1985), and Babbs, Resuscitation 13,
165—173 (1986), have demonstrated that iron chelators

causes changes in protein structure and function, which
“mature” with time and ultimately cause gross membrane

dysfunction. It is tempting to assume that the primary lesion
is an iron-catalyzed free-radical damage to membrane com

damage. The most promising compounds that interfere with
peroxidation generation are the lazaroids, modi?ed pred
nisones, described by J. M. McCall, Acta Anesthesia Bel
gica, First Antwerp Int. Trauma Symp., which have been
reported to be e?icacious if given during or after ischernia.
For example, Hall, et al, Stroke 19, 997-1002 (1988),

10438-10440 (1987), protected gerbils against brain dam

sis.

When ischernia is accompanied by a delayed acidosis
related damage, it seems likely that the lowering of pH

Mannitol, an osmotic agent and an oxygen scavenger, has

organs for transplantation. Superoxide dismutase (SOD) has

probably crucial, although osmolytic damage to dendritic
satisfactorily explained, however, how ischernia could cause
delayed neuronal death.

cord injury as well as in hemorrhagic stroke and ischernic

stroke. Most research which strongly implicates the primary
role of oxidative damage in ischernia/reperfusion injury in
brain can be grouped into either of two types of studies:
those which show protection by addition of agents prevent
ing peroxidative events, or those designed to observe free
radicals.
Although no drugs are currently approved for clinical use
in treating tissue damage due to ischemia, several com

is, at least to some extent, an excitotoxic lesion that is

triggered by the release of glutamate and/or asparate from
depolarized nerve endings. At the membrane and molecular
levels, calcium in?ux via NMDA-activated channels is

constitutes an important part of the ischernic necrosis. At

present, the evidence is relatively strong for an involvement
of free-radical mechanisms in vascular injury, but not for

damage affecting nerve and glial cells.
Reviews by Hall and Braughler, Free Radical Biol. Med.
6, 303-313 (1989), Kontos, Physiology of Oxygen Radicals,
ed. Taylor, Matalon and Ward, pp. 207-216 (Am. Physiol.
800., Bethesda, Md. 1986), and Ernster, Critical Care Med.

Several mechanisms may cause ischernic brain damage.
For example, the mechanisms responsible for selective neu
ronal vulnerability may be different from those that cause
glial swelling and extensive brain edema, and a third set of

seizures. Siesjo, Critical Care Med. 16, 954-963 (1988), has
grouped the numerous observations into four possible
mechanisms to explain the injury in brain. These include:

recent years, however, evidence has been obtained that
ischernia may cause conjugated dienes and malondialdehyde
to accumulate in the tissue. Nonetheless, it remains to be

protect animals from ischernia/reperfusion injury.
With regard to direct demonstrations of oxidative events
65

during ischernia/reperfusion injury in brain, there are perti
nent observations using spin-trapping techniques, salicylate
hydroxylation, protein oxidation, and nucleic acid oxidative

Re. 35,112
3
X is phenyl or

damage. Spin-trapping has provided clear evidence impli
cating free radical production dunng ischemia/reperfusion
injury. Imaizumi, et al, Neurological Res. 8, 214-220

(OR)n

(1986), showed that the spin-trap PBN when incubated with
rat brain homogenate of animals which had experienced
very low oxygen pressure for 5 min was able to trap an

apparently lipid-type radical. Kirsch, et al, Pediatric Res. 21,

wherein R is H,

202A (1987), stated in a preliminary note that PBN had
trapped free radicals in post ischemic brains from animals

pretreated with the spin-trap. McCay’s group have spin
trapped free radicals in mouse brain, Arch. Biochem. Bio

phys. 244, 156-160 (1986), and shown that spin-trapped

Y

free radicals of PBN are present in blood leaving the heart
of intact dogs recovering from a “stunn " myocardium, J.
Clin. Invest. 82, 476-485 (1988). As described, the free

and n is a whole interger from 1 to 5; or

radicals spin-trapped are apparently lipid-type free radicals
and appear within 1 min after release of occlusion and reach

peak intensity about 5 min after reperfusion starts. PBN

20

enhanced recovery of the post ischernic function of the
“stunned” heart.
In summary, while PBN has been used in a number of
research studies. there has been no data to support the

Y is a tert-butyl group that can be hydroxylated or acetylated
on one or more positions; phenyl; or

proposition that it could be useful in vivo, particularly with
respect to treatment of tissue damage in the central nervous

OW

system. In vivo, the drug must be able to (1) cross the blood
brain barrier and (2) act in a manner which reduces tissue

damage during or following ischemia.

r

30

It is therefore an object of the present invention to provide
composition and methods for use thereof which are useful in

preventing or reversing ischemic damage in vivo,, especially
in the CNS, spinal cord and eyes.
It is a further object of the present invention to provide

O

0

II

II

wherein W is C—CH3, NH-—C—Z,

35

O

0

II

II

C-CH3, C-OZ, or Z; and

compositions and methods for use thereof which are useful

in preventing or reversing free radical damage in vivo
resulting from infection and in?ammation.
It is another object of the present invention to provide
compositions and methods for use which prevent energy

40

Z is a C1 to C5 straight or branched alkyl group.
Based on animal studies, the dosage for treating damage
due to stroke is in the range of 10 to 300 mglkg.
The compositions are administered prior to or during
ischemia in an effective dosage to prevent or reverse pre

depletion of cells during ischemia.

disposition of the cells to damage resulting from depletion of

It is still another object of the present invention to provide
ATP (as demonstrated by in vivo NMR) and damage from
compositions and methods for use which are useful in the 45 free radical generation following reperfusion. The preferred
treatment of a variety of disorders in addition to those
method of administration is intravenously in humans for
treatment of stroke. The preferred method of administration
resulting from ischemia, including progressive neuronal loss
for treating in?ammation is by directed delivery to the site
from disease or drug and alcohol abuse and disorders
of in?ammation. Examples of diseases which can be treated
resulting from photooxidation and exposure to high pressure

include stroke, meningitis, progressive neuronal loss due to
Parkinson’s disease, senile dementia, and drug abuse, dis
orders arising from exposure to high pressure oxygen or
enriched oxygen environments, and bleeding into nervous

or enriched oxygen.

SUMMARY OF THE INVENTION
55

tissue as a result of trauma.

Compositions for treating tissue damage from ischemia
contain PBN, or active derivatives thereof, having the fol

BRIEF DESCRIPTION OF THE DRAWINGS

lowing general formula, in a suitable pharmaceutical carrier
for intravenous administration.
60

FIG. 1 is a graph of the dose-effect curve for the bene?cial
effects of PBN on transient ischemia-induced hyperactivity,

plotting locomotor activity versus PBN dose in mgl'kg.
Young adult gerbils were given a single dose of PBN 1 hr.
before 5 min of bilateral carotid occlusion. Twenty-four

hours later the change in spontaneous locomotor activity
65

wherein:

was determined. Control (con) value represent the level of
exploratory activity of a group of normal naive gerbils.
Saline (Sal) values were determined in gerbils injected with

Re. 35,112
5

6

saline 1 hr. prior to ischemia. Data presented represent the
mean (i'S.E.) for 6 gerbils per treatment group.
FIG. 2 is a graph of the etfect of PBN on the levels of
activity in successive 10 min intervals for the test described
in FIG. 1. Data presented represents the means (iS.E.) for 6
gerbils per treatment group: control (—0—0-—); 32 mg

still exhibit spin trapping of oxygen radicals are of bene?t by
bonding to the carbon-centered-free radicals to prevent
further damage by the modi?ed enzyme or other constituent.
As used herein, a free radical scavenger or spin trap reagent
is a molecule that will form a stable complex with a free
radical. A free radical carbon trap is a molecule in which the

PBN/kg (—A—A—); 100 mg PBN/kg (—[]—-[]—); and
300 mg PBN/kg (—°—-°—).

free radical is localized on a carbon atom or a nitrogen atom.

FIG. 3 is a graph of the effects of PBN on the post

ot-phenyl t-butyl nitrone (PBN), and derivatives thereof,

ischemic locomotor activity of aged gerbils (greater than 20

neous locomotor activity of gerbils, plotting locomotor

in a pharmaceutical vehicle suitable for intravenous admin
istration are useful in preventing or reversing CNS damage
following ischemia or in?ammation. As used herein,
ischemia is de?ned as a blockage of blood ?ow that results
in a lesion in the central nervous system (CNS), including
the spinal column and eyes. PBN has a number of advan
tages in the treatment of ischemia induced damage, includ

activity counts versus time (minutes). Saline treated group

ing being able to pass through the blood brain barrier and

(—0—0—) represents 5 of the 10 control gerbils
(—°—°—) tested. The data for PBN (--A—A—) rep

having no measurable eifect on normal or uninjured cells.

resents all 10 gerbils tested. Control values are for 6 gerbils.

a number of derivatives are also useful, including hydroxy
derivatives, especially 2-, 3- or 4~hydroxy PBN and mono-,

months of age) tested 24 hrs. after a 2 min period of
ischemia, as described in FIG. 1. Control (——°—O——);

saline (——0—0—); and 300 mg PBN/kg (—A—A——).
FIG. 4 is a graph of the effects of administration of 300
mg PBN on 15 min. ischemia-induced changes in sponta

PBN is the preferred active compound at this time, although

All data are expressed as the mean (iSE). Where no SE. is

indicated, it is within the dimensions of the symbol.
FIG. 5 is a graph comparing cumulative locomotor activ
ity counts over successive 10 minute periods for non

ischemic animals receiving saline (dark [1; 32 mg PBN/kg
(dark A); 100 mg PBN/kg (.); 300 mg PBN/kg (dark inverted
A); 500 PBN/kg (dark 0); 1000 mg PBN/kB (0); and 2000
mg PBN/kg (inverted A).

25

30

FIG. 6 is a bar graph comparing percent survival after a
lethal occlusion of the carotid arteries in gerbils treated with
either saline or 300 mg PBN/kg.

FIG. 7 is a graph comparing the percent carbonyl protein
of control in gerbils that have been subjected to ischemia,
ischemia followed by 15 minutes reperfusion, ischemia
followed by 60 minutes reperfusion, and ischemia followed
by 60 minutes reperfusion with preischemia administration
of 300 mg PBN/kg.
FIG. 8 is a graph comparing percent of glutamine syn
thase activity of control gerbils that have been subjected to
ischemia, ischemia followed by 15 minutes reperfusion,
ischemia followed by 60 minutes reperfusion, and ischemia
followed by 60 minutes reperfusion with preischemia
administration of 300 mg PBN/kg.
FIG. 9 is a graph correlating carbonyl/mg protein versus

di- and trihydroxy tert-butyl nitrone; esters, especially esters
which release 2-, 3, or 4-hydroxyphenyl t-butyl nitrone such
as the acetoxy derivative, 2-, 3-, or 4-carboxyphenyl t-butyl
nitrone. such as the ethyl derivative, or phenyl hydroxybutyl
nitrone, such as the acetoxy derivative; alkoxyl derivatives,
especially alkoxyl derivatives which release 2-, or 4-hydrox
yphenyl t-butyl nitrone, such as the methyl derivative; and
acetamide derivatives, especially acetarnide derivatives
which release 2-, or 4 arninophenyl t-butyi nitrone, such as

the acetyl derivative; diphenyl nitrone (PPN) and the analo
gous diphenyl nitrone derivatives. As used herein, “PBN"
refers to both ot-phenyl t-butyl nitrone and derivatives
thereof, unless otherwise stated. The active agent in the
compositions is N-tert-Butyl-a-phenylnitrone (PBN) or
derivatives thereof that are spin trap reagents and which also
40

act to prevent ATP depletion of cells.
The general formula for PBN and useful derivatives
thereof is:

45

glutmine synthetase speci?c activity, control (—[]--[]—);
10 minutes ischmia, no reperfusion (—-[inverted AHin
verted A]—), 10 minutes ischemia, 15 minutes reperfusion

X

50

([ A]~—[ A]—), 10 minutes ischemia, 60 minutes reperfusion
(—[O]—[O]—), and 10 minutes ischemia, 60 minutes
reperfusion and PBN (dark [1).

Y

wherein:
X is phenyl or
(0R)n

DETAILED DESCRIPTION OF THE
INVENTION

Following ischemia there is a signi?cant increase in free
radical production (both oxygen and carbon centered radi
cals). The initial damage to brain cells is thought to result

wherein R is H,
60

from the peroxidation products with subsequent damage
from secondary (carbon-centered) radicals. Eventually the
metabolic and synthetic pathways are damaged to such an
extent that the ceil dies. PBN and functionally equivalent
spin trapping derivatives that pass through the blood brain

barrier, prevent cell damage during and subsequent to
ischemia by decreasing or preventing ATP depletion, and

0

65

0

Y

and n is a whole interger from 1 to 5; or

Re. 35,112
other organs, and damage resulting from exposure to ioniz

ing radiation or photooxidation.
The PBN is preferably administered systemically, most
preferably intravenously, or orally, since this is the most
rapid and e?icient means for directing the active compound
to the site of free radical generation. However, other meth
ods of administration can be used, as when PBN is admin

Y is a tert-butyl group that can be hydroxylated or acetylated

istered intraperitoneally in the examples, or intranasally
through the pulmonary tract. The PBN can alternatively be

on one or more positions; phenyl; or

administered locally, by intramuscular or subcutaneous
injection, ointment, or delayed release implant.
Preferred pharmaceutical careers for intraveaous admin
istration are saline or phosphate bu?‘ered saline at physi
ological pH. In the preferred method, PBN is delivered to the
patient intravenously in a dosage in the range of 10 mg/kg/
hr, most preferably in the range of one to three mg/kglhr. The
dosage can be detetrained for the speci?c disease condition

OW
a

and/or species by conducting measurements, as described in

h’C-CI-Ig, l?C-OZ, or Z; and

detail below. In general, an effective dosage is that mount of
20

PBN that reduces enzyme activity loss by 25%, decreases
cell death by 25%, and/or maintains 25% or more of normal
function.
The present invention will be further understood with

Z is a C1 to C5 straight or branched alkyl group.
The compositions can also contain other active agents,
such as tissue plasrninogen activator, streptokinase, or other
clot dissolving compounds, other compounds which are
oxygen radical scavengers such as mannitol or compounds

reference to the following non-limiting examples demon
strating methods for determining effectiveness of PBN
administration for treatment of injury arising from ischemia

which prevent peroxidase generation, such as the lazaroids.

or inflammation and demonstration in animals of the pre

Examples demonstrate the utility of the compositions in
preventing brain damage and death in animals following
blockage of blood ?ow through the carotid artery to the

vention and/or reversal of damage from ischemia.
30

brain. Exemplary dosages of PBN ranged from 32 to 300
mg/kg of body weight in gerbils. The effective range of PBN
in humans and other mammals is between approximately 10

An accepted animal model for determining the e?‘ect of a

and 300 mg/kg. The compositions can be eifectively admin
istered prior to, during or after ischemia, and prevent or
decrease the extent of cellular damage.

35

compound on injury arising from a stroke is described by
Chandler, et al., J. Pharrn. Methods 14, 137-146 (1985).
Brie?y, Mongolian gerbils are anesthetized with pentobar
bital (40 mg/kg). A ventral rnidline incision is made in the
neck. Common carotids are exposed and separated from the
vagosympathetic nerve trunk. A loop of unwaxed dental

The use of compounds which are spin-traps that are

capable of scavenging oxygen radicals during reperfusion

floss (Johnson and Johnson) is placed around each carotid.

following ischemia, and which act to block ATP depletion of

The ends of the ?oss are each passed through one of the
lumens of a double lumen catheter (Dural Plastics and

the cell (which predisposes the cell to injury following
ischemia), represeats a truly unique approach to the man

agement of post-ischemic pathologic conditions, and fol
lowing ischemia associated with surgical procedures (e.g.,
by-pass surgery and transplantation of organs). Since the
trapping of endogenous free radicals is speci?c for only

Gerbil Stroke Model

Engineering, Dural, NSW, Australia). The catheter and den
tal ?oss are passed through the dorsal musculature and
exited at the dorsal surface of the neck. The catheter is ?xed
45

in position, directly above the carotid artery, using

those cells that have been exposed to the conditions that
result in the production of free radicals, the traps will have

cyanoacrylate adhesive at the exit site. The dental ?oss

speci?c enzymes, the spin traps offer a signi?cant improve

produced by gently pulling the looped dental ?oss until the

length is marked in order to assure that the animal does not

occlude the carotid during daily cleaning and exploratory
little or no effect on normal cells. The bene?cial effects will
activity. The ventral incision is closed with 9 mm wound
occur only in injured cells. Moreover, because the bene?cial
effect does not require the presence of speci?c receptors or 50 clips. After 48 hrs following instrumentation, ischemia is
ment in the treatment of ischemia/induced cellular dysfunc
tion and necrosis.

In addition, these compounds should be extremely useful
for the prophylactic treatment of chronic or periodic cyto
toxic conditions that involve free radicals. The CNS disease
conditions that are expected to be treatable using such
compounds include stroke, transient ischernic attacks,
Aizheimer necrosis, continued cell loss in Parkinsonism,

55

artery is occluded. Occlusion of the artery is associated with
loss of consciousness, ptosis and a change in breathing
pattern. Previous studies, using direct observation, have
demonstrated that complete interruption of ?ow occurs
under these conditions. The occlusion is maintained for 10
minutes and then the dental ?oss removed to allow complete
reperfusion. After reperfusion, the catheter is trimmed flush
with the surface of the neck.

meningitis, cardiac resuscitation-induced brain damage, and

The animals, male gerbils (50-60 gms), are purchased

damage arising as a result of trauma, especially head and

from Tumblebrook Farm, West Brook?eld, Mass, and
housed in groups of three for at least one week prior to

spinal injuries with associated bleeding from surrounding
tissues into the nervous tissues. It is expected that these

instrumentation. Following surgery, the gerbils are singly

compositions can also be used to treat a variety of other

housed in order to avoid the possible accidental induction of

disorders including damage to the eyes resulting from plac
ing very premature babies on high oxygen respirators, drug
and/or alcohol abuse-induced damage to the CNS, as well as

65

ischemia by cage mates. Food and water are available ad

libitum in the home cage. All gerbils are maintained under

a 12 hr light/dark cycle.

Re. 35,112
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EXAMPLE 1

treatment. Gerbils are given an ischemia/reperfusion treat
ment, or in the case of sham-operated controls, placed in the
animal holder but not occlusion, for a de?ned period. The
gerbils are killed by decapitation. The brains are removed
and placed on a cooled stage within 2 min. The cortex of
brain is isolated cold and stored at —80° C. for about one
week until it is extracted. The cortex is homogenized at ice

Determination of the Extent of Peroxidation

Damage in Brain Tissue

Measurement of Tissue Damage by Free Radical
Generation

temperature in a 0.5% NaCl solution (5 gm/rnl) and the
homogenate is then extracted with 2:1 chloroform-methanol

Tissue damage can be measured as a function of the

generation of free radicals. protein carbonyl concentration
increase, and decrease in glutarnine synthetase enzymatic

10

activity.
Free radicals are found in ischemialreperfusion injured

phase is recovered and bubbled with N 2 to obtain a concen

gerbil brains. There are several methods effective for mea

tration that is needed or the solvent of the organic phase is
evaporated to dryness and the residue redissolved in chlo
roform. Finally, the samples are transferred to a Pasteur

suring the generation of free radicals, including spin trap

ping and salicylate hydroxylation. Salicylate hydroxylation
can be used to monitor hydroxyl free radicals in vivo, since

pipette (sealed at the capillary end) and bubbled with N2 for
5 min. The pipettes are then placed in the sample cavity of

hydroxylation products (2,5-and 2,3-dihydroxybenzoic
acids, DHBA) are present in the brains of gerbils pretreated
with salicylate. The amount of DHBA correlates closely

mixture (v/v) to a ?nal dilution of 20-fold the volume of the

tissue sample. The crude extract is washed thoroughly with
0.5% NaCl (5:1, v/v) and the mixture is allowed to separate
into two phases by standing at 4° C. for 2 hr. The organic

an IBM Bruker ESP300 EPR spectrometer and scanned for
20

with the amount of brain injury observed in this model, as

the presence of spin adducts. The usual spectrometer settings

are as follows: Microwave power 19.8 mW; modulation
amplitude 0.9756, time constant 1310.72 ms; scan range
100 G;, and scan time 6 min. All spectra are recorded at
room temperature. The coupling constants can be directly
25 obtained from the instrument and since since the instrument
all tissue necrosis is also indicated by a decrease in the
is controlled by an online computer, simulated spectra of a
enzymatic activity of glutamine synthetase (GS) in is
mixture of spin-trapped free radials can be compared with
chemic-lesioned gerbil brain. This decrease increases as
the bona?de spectrum obtained in order to make prediction

shown by Cao, et Neuroscience Lett. 88, 233-238 (1988).
Oxidative damage to gerbil brain proteins can be assessed by
protein carbonyl group increase, which occurs as the
ischemic-lesioned gerbil brain is allowed to reperfuse. Over

reperfusion time increases, such that at 60 min the GS
activity is decreased about 35% from normal values. The
enzymatic activity of GS is highly sensitive to metal cata

lyzed oxidative damage. Therefore its loss supports the
notion that metal catalyzed oxidative damage does occur in
the reperfusion phase of the ischemic-lesioned gerbil brain.
GS enzymatically converts glutamate to glutamine and thus
a decrease in its activity may allow the buildup of glutamate,
an excitatory toxic amino acid.

30
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Utilizing the ischernia/reperfusion lesioned brain of ger
bils, it was demonstrated that oxidative damage was occur

spin-trapped in ischemia/reperfusion injury in rat heart by
Bolli and McCay, J. Clin. Invest. 82, 476-485 (1988).
The production of free radicals during ischemia/reperfu
sion induced injury in the gerbil brain was tested using spin

ring, with the evidence as follows: (1) increased levels of

salicylate hydroxylation products, implicating increased
hydroxyl free radical flux in lesioned brain, (2) increased
levels of protein oxidation and a loss of glutamine syn
thetase activity in lesioned brain, (3) free radical formed

from spin-traps in lesioned brains, (4) spintrap mediated
protection from brain ischemia/reperfusion injury, and (5) an
increased peroxidation capacity of brain during the reper

tapping. Both treated and control animals were administered
45

Spin-trapping and HPLC with electrochemical detection
(LCED) are used to quantitate hydroxylation products of
salicylate, formed in part by hydroxyl free radical addition,

the spin trap PBN (tx-phenyl-t-butyl nitrone) before the
experimental treatments. The data demonstrate that large
free radical signals were obtained from the extracts of brains
of ischemia/repcrfusion treated gerbils in contrast to very

fusion phase after an ischernic insult.

Demonstration of in Vivo Oxygen Free Radical
Flux by Spin~Trapping and HPIJC with
Electrochemical Detection

regarding the tapped free radicals. An extensive data base of
spin coupling constants taken in ditferent solvents using
di?erent systems is used for comparison purposes.
Spin-traps react with free radicals to form adducts, the
electron spin resonance (ESR) spectrum, which provides a
mechanism to deduce the chemical identity of the free
radicals tapped. The method used for in vivo spin trapping
was developed by Dr. P. B. McCay in combination with Dr.
Ed Janzen, as reported by Lai, et al., Arch. Biochem.
Biophys. 244, 156-160 (1986). Free radicals have been

little signals from sham-operated control animals. Surpris
50

ingly, the radicals are not what would be expected when a
spin-trap reacts with a free radical to produce a spin adduct.
A six-line spectrum is expected from the spin-adduct of a
free radical of PBN. The six-line spectrum is due to the free

electron interacting with the spin l/z nuclear magnetic
55 moment of the proton as well as the spin of 1 from the

nitrogen of the nitroxyl group. In contrast, these spectra are
only three lines, and are therefore due to the free electron

and hydroxyl free radical adducts to DNA and RNA. The
extreme sensitivity of the LCED methodology, on the order
of 103 to 104 gain over optical methods, is a distinct
advantage when attempting to ascertain the ?ux of oxygen

interacting with the nitroxyl nitrogen only, which means that
available protons are displaced at a distance such that thye
are not in?uencing the free electron.

free radicals in vivo, which may only reach 10-9 M under

The most likely explanation for the results is that PBN

high oxidative stress conditions. It has been demonstrated in

?rst traps a free radical, possibly a lipid carbon free radical,
after which the spin-adduct is then oxidized to a nitrone
which then traps another free radical, yielding a nitroxide

biochemical systems that OH radicals could be trapped by
salicylate and quantitated using LCED.
Electron spin resonance of brain lipid extract is measured
as follows. Gerbils are administered spin-trap dissolved in

saline stored cold (protected from light) LP. 1 hr prior to

65

having properties producing the observed spectra.
Two other spin-traps, DMPO (5,5-dimethylpyrroline-N
oxide) and POBN (ot-pyridyl-l-oxide-N-t-butylnitrone),
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both of which have diiferent chemical structures from PBN,

statements are presented in FIGS. 1, 2, 3 and Table 1. Table
I shows that animals given PBN I.P., dissolved in saline, at
a dosage of 300 mglkg, 60 min prior to 15 min ischemia,

yielded nitroxide spectra (very similar, 3-lines, yet with
slightly different nitrogen coupling constants and different

which is followed by 24 hr reperfusion, protected the
animals from death, that is, the animals lived for longer than
7 days, the time point when lethality is evaluated. 0f the
control animals which received saline, 50% of the yound and

intensities) as with PBN in the ischemia/reperfusion treated
gerbils. It is pertinent to note that if the chloroform/methanol
extract of brains of animals which have been pretreated with
PBN is allowed to stand at room temperature for 24 hours,
then the 3-line signal decays. If, however, more PBN is then

100% of the old gerbils had died as of the seventh day.
Gerbils, which have received a brain ischernic insult
resulting in permanent injury, ?rst exhibit a lethargic reac
tion then a characteristic increase in spontaneous locomotor
activity above controls at 4 hours after ischemia. The

added to the extracts and it is then incubated for 24 hours
trapped radial signals are observed in the extract of
ischemiclreperfusion animals, but signals are not seen in the

sham-operated controls. Computer simulation of the signals

lesion-induced hyperactivity continues for several days.
Drugs that protect the animals from ischemia/reperfusion
injury prevent the characteristic rise in spontaneous activity.
PBN was effective at various dosages in protecting against
ischemialreperfusion induced hyperactivity, as demon

developing show that three free radicals are present. One has
parameters equivalent to the three line nitroxide observed
previously and the other two are spin-trapped carbon free

radicals, possibly lipid radicals. These observations indicate
that oxidative events were started in the ischernic brains but
not in the sham-operated controls and these events are
carried over, at least in part, in the lipid extracts.

strated by Table l and FIG. 1. It can be seen that saline
treated animals given a 5 min ischemia insult had hyperac

tivity signi?cantly higher than sham-operated controls 24 hr
20

Demonstration of lschemia/Repe?’usion Induced
Increased Peroxidation Capacity of the Brain
Brain homogenate at ice temperature does not spontane
ously peroxidase, yet if the temperature is raised to 37° C.
there is, in contrast to almost all other tissue homogenates,
spontaneous peroxidation. The rate of peroxidation varies
with brain region and is highly correlated with the total iron
content of the brain region. Gerbil brain homogenate per

25

after ischemia. However, animals which had received PBN
at 32 or 100 mg/kg 1 hr prior to ischemia had no elevated

hyperactivity. PBN at 300 mg/kg caused a decreased activity
over controls. Data comparing activity at the 24 hr reperfu
sion time of sham-operated controls with 2 min ischemia, 5
min ischemia and 15 min ischemia lesioned animals, which
had received either saline or 300 mglkg PBN, are shown in

FIGS. 2, 3 and 4. The data clearly demonstrate that the high
dose of PBN caused a reduction in ischemia induced hyper

oxidizes more rapidly than rat brain. The susceptibility to 30

activity to levels of the control or lower.

peroxidation of brain homogenate after it has experienced an
ischemia/reperfusion insult and the effect of time of reper

TABLE 1

fusion was determined. The data were collected from 176

I-listopathological Scores in Gerbils 7 days after 5 min
of Global Cortical Ischemia.

gerbils. At every time point sham-operated animals were
used as controls. The data show that after 10 min of ischemia 35
there is, if reperfusion is not allowed to occur, a decrease in

Group

the rate of peroxidation. If reperfusion is allowed to occur

Control (no ischemia)
32 mg PBN/kg
100 mg PBN/kg
300 mg PBN/kg

after ischemia, then the rate of peroxidation increases sig
ni?cantly over sham-operated control animals in a time
course fashion. The increase is most rapid in the ?rst 60 min
then slows, reaching a maximum at 7 days following

In order to obtain parameters relative to acute toxicity of
tigated at a wide range of concentrations. The data are shown
45

amount of spontaneous peroxidation above sham-operated
controls. Thus not only does pentobarbital protect gerbils
from the damage brought about by ischemia/reperfusion
50

trols, demonstrating a direct correlation between increased

55

brain homogenate peroxidation.

at high PBN concentrations is an induced lethargic response
which disappears after 24 hours.
The e?‘ect of PBN administration on percent survival of
animals given lethal strokes (15 min ischemia) is shown in
FIG. 6. 50% of the animals given 15 minutes ischemia died.
With pre-ischemic treatment with PBN, 100% of the animals
survived.
Ischemialreperfusion induced oxidative damage to brain
proteins. Gerbil brains which had received various treat
ments were analyzed for carbonyl groups on proteins, a

EXAMPLE 2

The spin-trap PBN often considerable protection to the
gerbil from brain injury brought on by an ischemia/reper
fusion insult and in addition helps prevent death which often
accompanies the brain injury. The data demonstrating these

in FIG. 5. Only at PBN concentrations of 1000 mg/kg and
higher was there any alteration in activity noted. PBN at
2000 mg/kg was not lethal to animals. The one noted effect

injury, there is no increased peroxidation of the brain homo
genate from pentobarbital treated animals as compared with
untreated animals. Pre-treated animals lesioned by 15 min
ischemia/l5 min reperfusion had spontaneous brain homo
genate peroxidation about 15% above sham-operated con

Demonstration of the Protective Effect of

(i5)
(17)
(1.4)
(1.5)

PBN, total cumulative activity of normal gerbils were inves

followed by 15 min reperfusion have no increase in the

Spin-Traps in Ischemia/Reperfusion Induced Brain
Injury in Gerbils

4.3
2.5
2.8
1.7

"N = 6 gerbils per group.

ischemia, after which it decreases to values which were still

higher than controls at 14 days.
Brains from gerbils which have been pretreated with
pentobarbital and then given a 15 min ischemia period

Score

60

measure of oxidative damage to protein, and glutamine
synthetase activity. The results are shown in FIGS. 7 and 8
and compared in FIG. 9.
FIG. 7 shows oxidative damage to protein as measured by

carbonyl content as a percentage of a control gerbil brain
given a ten minute ischemia at the indicated time of reper
65 fusion. 300 mg PBN/kg was administered one hour prior to
the onset of ischemia. Carbonyl protein content was elevated
above control levels in 10 min ischemia treated brains
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without reperfusion.

obvious to those skilled in the art from the foregoing detailed
description. Such modi?cations and variations are intended
to come within the scope of the following claims.
We claim:
1. A method for in vivo treatment of oxidative CNS tissue

Reperfusion for 15 rnin did not enhance carbonyl protein
above the ischemia only values. After 60 min reperfusion
there was a signi?cant increase in carbonyl protein. PBN
pretreatment prevented this rise.
FIG. 8 shows the oxidative damage to glutarnine syn

damage [resulting from ischemia or in?ammation] compris
mg:

thetase activity as a percentage of a control gerbil brain
given a ten minute ischemia at the indicated time of reper
fusion. 300 mg PBN/kg was administered one hour prior to

the onset of ischemia. Glutamine synthetase (GS) activity

administering oi-phenyl t-butyl nitrone [and derivatives]
or a derivative thereof [having spin trapping activity
10

and preventing ATP depletion in vivo in tissue] having
the formula:

was slightly lower than control values after ischemia with no

reperfusion. With increasing reperfusion time, there was a
dramatic loss in GS activity such that after 60 min reperfu
sion, only 65% of the activity remained. PBN pretreatment
of the animals prevented this loss in GS activity. Since this
enzyme is considered to be a glial cell marker, this data
indicates post ischemic damage also occurs in glial cells.
FIG. 9 shows that there was a good correlation between
the loss of GS activity versus accumulation of carbonyl

protein when all of the samples analyzed are compared.

11

O

\
C=

/
X

Y

wherein:
20

X is phenyl or

Ischemia/Reperfusion Induced Gene Expression
The levels of mRNA for c-fos and c~jun were examined
in gerbil brain cortex after ischemia/reperfusion. The results
of 10 min of ischemia followed by 60 min of reperfusion
demonstrated that both c-fos and c-jun mRNA levels are
elevated within 60 min after the insult. Control animals and
animals subjected to the surgery showed lower levels of
c-fos mRNA was markedly enhanced. Pentobarbital pre
treatment, which protects the animals from ischemia/reper

{ORln
25

wherein R is H,
30

fusion injury, prevented the induced expression of the c-fos
Y

gene, whereas no pretreatment caused a large increase in
c-fos mRN A. PBN pretreatment suppresses the level of
35

c-fos induction in the ischemia/reperfusion injury.

and n is a whole integer from 1 to 5; or

01d gerbils are much more sensitive to brain ischemia!

reperfusion injury than young animals, as shown in Table 2.
Data are expressed as number surviving/total tested.
40

TABLE 2
Effects of PBN pretreatments on post reperfusion

lethality in young adult gerbils (3—4 months of age).

Y is a tert-butyl group that can be hydroxylated or

Treatment

Age

(300 mg PEN/kg)

Saline

control
15 min ischemia
10 min ischemia

young
young
retired

15/15
10/10
4/4

15/ 1 5
5110*
0/4

acetylated on one or more positions; phenyl; or

OW

breeders; (18 me.)
*All surviving gerbils were subsequently tested for behavioral effects at 24 hr. 50

post-ischemia.

55

In preliminary studies, the effectiveness of two other

spintraps, DMPO and POBN, in preventing the acute effects
of an ischemic insult to brain was tested. The results indicate 60

that both DMPO and POBN appear to olfer some protection,

0

0

II

II

Z is a C1 to C5 straight or branched alkyl group; [and] in
a pharmaceutically acceptable carrier for delivery of the

ot-phenyl t-butyl nitrone or derivative thereof to [the
CNS of] a patient in need of such treatment in a dosage

but DMPO was less effective than POBN which was less

effective to prevent or reverse oxidalive CNS tissue

effective than PBN.
Modi?cations and variations of the present invention,

methods using the compositions for the treatment of tissue
damage resulting from ischemia or in?ammation, will be

II

c-crn, c-oz. or z; and

Than PBN

compositions containing PBN and derivatives thereof, and

0

II

wherein W is C-CHg, NI-I-C-Z,

EXAMPLE 3

E?ectiveness of Spin-Trapping Reagents Other

O

damage [resulting from ischemia of inflammation] not
associated with bacterial toxins.
65

2. The method of claim 1 wherein the phenyl butyl nitrone
derivatives are selected from the group consisting of

hydroxy PBNs, PBN esters, acetoxy PBNs, alkyl PBNs,

Re. 35,112
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alkoxyl PBNs, phenyl PBNs.
3. The method of claim 1 wherein the PBN derivative is
functionalinzd to release in vivo a compound selected from

the group consisting of 2-, 3-, and 4-hydroxyphenyl t-butyl
nitrone; 2-, 3-, and 4-hydroxyphenyl t-butyl nitrone; 2-, 3-,
and 4-carboxyphenyl t-butyl nitrone; and 2-, 3-, and 4-ami
nophenyl t-butyl nitrone.

Y is a tert-butyl group that can be hydroxylated or
acetylated on one or more positions; phenyl; or

4. The method of claim 1 comprising as the active

ingredient u-phenyl t-butyl nitrone.
5. The method of claim 1 further comprising administer
ing an agent selected from the group consisting of strep
tokinase, tissue plasrninogen activator, mannitol, and laz

OW

aroids.
6. The method of claim 1 wherein the PBN and deriva
tives thereof is in a pharmaceutical carrier delivering an

elfective dosage to a patient to prevent reperfusion injury of
CNS tissue.
7. The method of claim 1 wherein the PBN and deriva
tives thereof is in a pharmaceutical carrier delivering an 20

eil‘ective dosage to a patient to prevent CNS tissue damage
from in?ammation.
8. The method of claim 1 wherein the PBN and deriva
tives thereof is provided in a dosage of 10 to 300 mg PBN/kg

body weight.
9. The method of claim 1 wherein the composition
administered during or immediately after a stroke.
10. The method of claim 1 wherein the composition is
administered to a patient having a progressive neuronal
disorder.

11. The method of claim 1 wherein the composition is
administered to a patient exposed to high pressure oxygen or
an oxygen enriched environment.
12. The method of claim 1 wherein the composition is
administered to a patient to mitigate damage to cells from

ll

0

I!

ll

Z is a C1 to C5 straight or branched alkyl group [further
comprising a compound selected from the group con
25

sisting of streptokinase, tissue plasrninogen activator,
mannitol and lazaroides]
a pharmaceutically acceptable carrier for [intravenous]
administration to a patient,

30

wherein the ot-phenyl nitrone is in an amount e?ective to

prevent tissue damage [resulting from ischemia or
in?ammation] not associated with bacterial toxins
wherein the nitrone [and further compound are] is
35

present in e?’ective amounts.

15. The composition of claim 14 wherein the phenyl butyl
nitrone derivatives are selected from the group consisting of
hydroxy PBNs, PBN esters, acetoxy PBNs, alkyl PBNs,

13. The method of claim 1 wherein the composition is
administered to a patient su?‘ering from meningitis.
14. A composition for in vivo treatment of oxidative CNS
tissue damage [resulting from ischcmia or in?ammation] not
associated with bacterial toxins comprising:

alkoxyl PBNs, phenyl PBNs.
16. The composition of claim 14 wherein the PBN deriva
tive is functionalized to release in vivo a compound selected

ot-phenyl t-butyl nitrone [and derivatives] or a derivative

from the group consisting of 2-, 3-, and 4~hydroxyphenyl

thereof [having spin trapping activity and preventing
ATP depletion in vivo in tissue] of the formula:
45

t-butyl nitrone; 2-, 3, and 4-hydroxyphenyl t-butyl nitrone;
2-, 3-, and 4-aminophenyl t-butyl nitrone.
17. The composition of claim 14 comprising as the active

O‘

ingredient ot-phenyl t~butyl nitrone.

\ C=N+/
/
x

O

H

C-CH3, C-OZ, orZ; and

exposure to a chemical agent.

H

O

whereinW is C-CHg, NH—C——Z,

Y

50

X is phenyl or

18. The composition of claim 14 wherein the PBN and
derivatives thereof is in a pharmaceutical carrier delivering
an eifective dosage to a patient to prevent reperfusion injury.
19. The method of claim I wherein the oxidative CNS
tissue damage is associated with ischemia and wherein the

route of administering is intravenous.
20. The method of claim 19 wherein the ischemia is stroke

(OR)n

and wherein the e?’ective dose is from 10 to 300 mg of

nitrone compound per kg of body weight.
21. The method of claim 10 wherein the progressive
neuronal disorder is due to Parkinson ’s disease.
22. The method of claim I 0 wherein the progressive

wherein R is H,

neuronal disorder is due to senile dementia.

23. The method of claim I wherein the oxidative CNS

damage is associated with in?ammation.
65

24. The method of claim I wherein the oxidative CNS

damage is associated with meningitis.
and n is a whole integer from 1 to 5; or

25. The method of claim I wherein X is
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(OR)n

(OR)n
5

and R is H.

and R is H or Z

29. The composition of claim 2 7 wherein Y is tert-butyl,

26. The method of claim 25 wherein Y is a ten-butyl
8'0"!’-

X is
10

27. A composition comprising:
(OR)n

nitrone compound of the formula:
H

0

15

C:

andRisZ

X

30. A composition comprising:
nitmne compound of the formula:

Y

wherein:

20

X is phenyl or

H\ c=1~1+ /0
/

(OR)n

\

X

25

Y

wherein:
X is phenyl or

wherein R is H,
30

(OR)n
O

O

I!

/

Z—C—.or Z; or —CH=N

,

\
Y

35

wherein R is H,
and n is a whole integer from I to 5; or
O

0

II
0

/

Z—C—, or Z; or ——CH=N

40

\
Y

and n is a whole integer from I to 5; or
Y is a tert-butyl group that can be hydroxylated or acetylated 45
on one or more positions; phenyl; or

OW
1

50

Yis a tert-butyl group that can be hydroxylated or acetylated
on one or more positions: phenyl; or

wherein W is
OW
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1

O

H

II

II

C-CH3, NH-C-Z, 0-02. or Z;

wherein W is

and
Z is a C1 to C5 stright or branched alkyl group;

subject to the proviso that X is not phenyl when Y is
tert-butyl, in a pharmaceutically-acceptable, orally
administrable carrier:

28. The composition of claim 27 wherein Y is tert-butyl,
X is

0

0

II

II

II

C—-CH3, NH-C-Z. C——0Z, or Z;
65

and
Z is a C1 to Cs straight or branchedI alkyl group;
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subject to the proviso that X is not phenyl when Y is
tert-butyl in pharmaceutically-acceptable, intrave-

32. The composition of claim 30 wherein Y is tert-butyl,
X is

nously-administrable carrier.
31. The composition of claim 30 wherein Y is tert-butyl,
X is

5

g

(011)“

10

and R is Z.
andRisH.
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